PXMD vs. AMPE, CALA, CMRA, EFTR, CLVR, ONCSQ, SMFL, ATNFW, LBPSW, and AEHAW
Should you be buying PaxMedica stock or one of its competitors? The main competitors of PaxMedica include Ampio Pharmaceuticals (AMPE), Calithera Biosciences (CALA), Comera Life Sciences (CMRA), eFFECTOR Therapeutics (EFTR), Clever Leaves (CLVR), OncoSec Medical (ONCSQ), Smart for Life (SMFL), 180 Life Sciences (ATNFW), 4D pharma (LBPSW), and Aesther Healthcare Acquisition (AEHAW). These companies are all part of the "pharmaceutical products" industry.
PaxMedica vs.
Ampio Pharmaceuticals (NYSE:AMPE) and PaxMedica (NASDAQ:PXMD) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability, community ranking and risk.
In the previous week, Ampio Pharmaceuticals had 1 more articles in the media than PaxMedica. MarketBeat recorded 1 mentions for Ampio Pharmaceuticals and 0 mentions for PaxMedica. Ampio Pharmaceuticals' average media sentiment score of 0.00 equaled PaxMedica'saverage media sentiment score.
PaxMedica received 1 more outperform votes than Ampio Pharmaceuticals when rated by MarketBeat users. Likewise, 100.00% of users gave PaxMedica an outperform vote while only 0.00% of users gave Ampio Pharmaceuticals an outperform vote.
5.7% of Ampio Pharmaceuticals shares are owned by institutional investors. Comparatively, 4.9% of PaxMedica shares are owned by institutional investors. 3.3% of Ampio Pharmaceuticals shares are owned by insiders. Comparatively, 1.0% of PaxMedica shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Ampio Pharmaceuticals has a beta of 3.9, indicating that its stock price is 290% more volatile than the S&P 500. Comparatively, PaxMedica has a beta of -1.32, indicating that its stock price is 232% less volatile than the S&P 500.
Ampio Pharmaceuticals' return on equity of 0.00% beat PaxMedica's return on equity.
Summary
Ampio Pharmaceuticals beats PaxMedica on 7 of the 9 factors compared between the two stocks.
Get PaxMedica News Delivered to You Automatically
Sign up to receive the latest news and ratings for PXMD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart
PaxMedica Competitors List
Related Companies and Tools
This page (NASDAQ:PXMD) was last updated on 5/23/2025 by MarketBeat.com Staff